Clinical trials: glp1 Agonist
Healthy
a Study of JY09 in Chinese Healthy Subjects
JY09，is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist,constructed with Exendin-4 and human Immunoglobulin G2 (IgG2) Fc fragment.Preclinical studies show that JY09 exhibit the expected GLP-1-mediated…
- Trial name
- NCT02971722
- Testing
- JY09
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
Lower Urinary Tract Symptoms, Stress Urinary Incontinence
Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy
The purpose of this study is to compare change in pelvic floor symptoms between patients receiving medical therapy for weight loss and surgical treatment for weight loss.
- Conditions
- Lower Urinary Tract Symptoms, Stress Urinary Incontinence, Urge Urinary Incontinence, Overactive Bladder
- Trial name
- NCT07175805
- Testing
- Bariatric Surgery, GLP1 receptor agonist
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Hartford HealthCare
Alcohol Dependence, in Remission, Addiction, Alcohol
Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?
The study is a double-blinded, randomized, placebo-controlled, 26-weeks clinical trial. The objective of the trial is to investigate the effects of the GLP-1 receptor agonist Bydureon® (exenatide) vs.
- Trial name
- EXALT (NCT03232112)
- Testing
- Exenatide 2 MG Injection, BD PosiFlush (saline)
- Where
- Denmark
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Endoscopy, Digestive System, GLP1-R-related Disease
Evaluate the Detection of Retained Gastric Contents and Assess Safety Using the Flower Capsule Endoscopy in Healthy Individuals and GLP-1 Receptor Agonist Users
Clinical Study Overview Feasibility Study Plan (Study 1: Healthy Participants) Study 1- Confirming Flower capsule performance characteristics in detection of retained gastric contents greater than 1.5mL/kg in Healthy volunteers…
- Trial name
- NCT06927401
- Testing
- Flower
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Asian Institute of Gastroenterology, India
Gastroparesis, Functional Dyspepsia
Effects of Liraglutide on Body Surface Gastric Mapping
Aim 1: To investigate, in healthy participants, the effect of liraglutide injection on gastric electrophysiology (as measured by body surface gastric mapping using the Gastric Alimetry device) during an 13-dayramping dose of…
- Conditions
- Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome, Healthy
- Trial name
- NCT06500130
- Testing
- Body Surface Gastric Mapping
- Where
- New Zealand
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Alimetry
Prader-Willi Syndrome
Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome
The purpose of this study is to investigate the effects of a GLP-1 agonist on satiety hormones in patients with Prader-Willi Syndrome (genetic defect causing obesity).
- Trial name
- NCT00551343
- Testing
- Exenatide
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Garvan Institute of Medical Research
Healthy Participants
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.
- Trial name
- NCT07723833
- Testing
- Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B
- Where
- 2 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity
Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMF-650 in Otherwise Healthy Overweight or Obese…
- Trial name
- NCT07223216
- Testing
- BMF-650
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Biomea Fusion Inc.
Safety and Tolerability
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
The trial is a Phase 1, single-centre, randomised and double-blind within cohorts, placebo-controlled, sequential multiple ascending dose trial including three cohorts in Part 1 in a semi-parallel design and one cohort in Part 2…
- Trial name
- NCT06000891
- Testing
- ZP7570
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Laxity; Skin
Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist
The primary objective is to assess the safety and efficacy of the AGE Serum in improving the appearance of skin in post-menopausal subjects on HRT and non-HRT who are takingGLP-1 agonist therapy through the use of investigator…
- Trial name
- NCT07558603
- Testing
- On GLP1 plus HRT, On GLP1 Only
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
Diabete Type 2
A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil
This is a Phase I, randomized, double-blind, placebo-controlled, single-dose study in healthy adult participants in Brazil to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of…
- Trial name
- BRIDGE-BR (NCT07518121)
- Testing
- Efsubaglutide Alfa Injection
- Where
- Brazil
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Obesity
POSE2.0 With GLP-1 Agonist for Obesity Management
Determine the effect on weight loss and obesity-related comorbidities in patients receiving the POSE 2.0 procedure with sequential use of Liraglutide at 6 months compared to those receiving Liraglutide and then undergoing the…
- Trial name
- NCT05705388
- Testing
- POSE2.0 Endoscopic Gastric Remodeling, Liraglutide injection
- Where
- United Arab Emirates
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Emirates Health Services (EHS)
Alopecia
Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use
A single-center, open-label clinical study to evaluate whether a dietary supplement can reduce hair loss in women with GLP-1-associated telogen effluvium. Participants will use the supplement for 120 days.
- Trial name
- GLP-1 (NCT07783113)
- Testing
- Dietary Supplement for Hair Loss
- Where
- Brazil
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Farmoquimica S.A.
Obesity
CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users
This study aims to assess the impact of GLP-1 receptor agonists, semaglutide and tirzepatide, on food cravings and diet quality in individuals with overweight or obesity.
- Trial name
- NCT06467604
- Testing
- Surveys, Indirect Calorimetry, Body composition
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Hyperlipidemia
Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans
Exenatide acutely inhibits intestinal lipoprotein particle production. We are unable to speculate whether exenatide affects hepatic lipoprotein production in humans since there is currently no evidence from animal models or in…
- Trial name
- NCT01056549
- Testing
- exenatide
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
GI Symptoms
A Pilot Study Evaluating the Impact of a Prebiotic Soda on Gastrointestinal Symptoms in Users of GLP-1 Agonists
The main objective of this study is to assess the impact of drinking a prebiotic soda on the gastrointestinal (GI) symptoms associated with the use of GLP-1 receptor agonists compared to usual fluid intake.
- Trial name
- NCT07744360
- Testing
- Prebiotic Soda
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Olipop, PBC
Normal Healthy Volunteer, Safety After Oral Intake
A Research Study to Evaluate BLX-7006 in Healthy Adults
This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection.
- Trial name
- NCT07140055
- Testing
- BLX-7006
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Healthy, Hepatic Insufficiency
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to…
- Trial name
- NCT05882032
- Testing
- LY3502970
- Where
- 4 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
FutureShape Family
The number of adults and children living with obesity is increasing worldwide. Once childhood obesity has developed, more than 80% of children carry the obesity into adulthood, with a high risk of cardiometabolic disease, poor…
- Trial name
- NCT07872904
- Testing
- Family Care, Standard Care, Semaglutide (administered by PDS290 pen-injector)
- Where
- Denmark
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Signe Torekov
Sarcopenia
Creatine Supplementation During GLP-1a Therapy
GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of…
- Trial name
- NCT07625202
- Testing
- Dietary supplementation during a 12 week resistance-training program (creatine)
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan